Bio-Techne Corp (TECH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 29.51 is considered Undervalued compared with the five-year average of 41.31. The fair price of Bio-Techne Corp (TECH) is between 56.64 to 88.75 according to relative valuation method. Compared to the current price of 55.43 USD , Bio-Techne Corp By Undervalued By 2.13%.

Relative Value

Fair Zone

56.64-88.75

Current Price：55.43

2.13%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Bio-Techne Corp (TECH) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Bio-Techne Corp (TECH) has a current Price-to-Book (P/B) ratio of 4.73. Compared to its 3-year average P/B ratio of 5.41, the current P/B ratio is approximately -12.62% higher. Relative to its 5-year average P/B ratio of 7.09, the current P/B ratio is about -33.32% higher. Bio-Techne Corp (TECH) has a Forward Free Cash Flow (FCF) yield of approximately 2.41%. Compared to its 3-year average FCF yield of 2.23%, the current FCF yield is approximately 8.06% lower. Relative to its 5-year average FCF yield of 2.07%, the current FCF yield is about 16.64% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TECH competitors is 36.90, providing a benchmark for relative valuation. Bio-Techne Corp Corp (TECH.O) exhibits a P/S ratio of 7.51, which is -79.66% above the industry average. Given its robust revenue growth of -0.39%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TECH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TECH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TECH currently overvalued or undervalued?

What is Bio-Techne Corp (TECH) fair value?

TECH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Bio-Techne Corp (TECH) is between 56.64 to 88.75 according to relative valuation method.

How does TECH's valuation metrics compare to the industry average?

The average P/S ratio for TECH's competitors is 36.90, providing a benchmark for relative valuation. Bio-Techne Corp Corp (TECH) exhibits a P/S ratio of 7.51, which is -79.66% above the industry average. Given its robust revenue growth of -0.39%, this premium appears unsustainable.

What is the current P/B ratio for Bio-Techne Corp (TECH) as of Mar 03 2026?

As of Mar 03 2026, Bio-Techne Corp (TECH) has a P/B ratio of 4.73. This indicates that the market values TECH at 4.73 times its book value.

What is the current FCF Yield for Bio-Techne Corp (TECH) as of Mar 03 2026?

As of Mar 03 2026, Bio-Techne Corp (TECH) has a FCF Yield of 2.41%. This means that for every dollar of Bio-Techne Corp's market capitalization, the company generates 2.41 cents in free cash flow.

What is the current Forward P/E ratio for Bio-Techne Corp (TECH) as of Mar 03 2026?

As of Mar 03 2026, Bio-Techne Corp (TECH) has a Forward P/E ratio of 29.51. This means the market is willing to pay $29.51 for every dollar of Bio-Techne Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bio-Techne Corp (TECH) as of Mar 03 2026?

As of Mar 03 2026, Bio-Techne Corp (TECH) has a Forward P/S ratio of 7.51. This means the market is valuing TECH at $7.51 for every dollar of expected revenue over the next 12 months.

TECH Valuation